NCT04890093: Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

NCT04890093
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 12 Years to 39 Years (Child, Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: Breast cancer patients are only eligible for phase 1 of the study
Exclusions: Patients 40 years of age or older
https://ClinicalTrials.gov/show/NCT04890093

Comments are closed.

Up ↑